

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 1 512 744 A1

(12)

# EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

- (43) Date of publication: 09.03.2005 Bulletin 2005/10
- (21) Application number: 03733346.5
- (22) Date of filing: 10.06.2003

- (51) Int CI.7: **C12N 15/12**, C12N 1/21, C12N 5/10, C07K 14/435, C07K 19/00, G01N 21/78
- (86) International application number: PCT/JP2003/007336
- (87) International publication number:WO 2003/104460 (18.12.2003 Gazette 2003/51)
- (84) Designated Contracting States:

  AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
  HU IE IT LI LU MC NL PT RO SE SI SK TR
  Designated Extension States:

  AL LT LV MK
- (30) Priority: 10.06.2002 JP 2002168583
- (71) Applicants:
  - Riken
     Wako-shi, Saitama 351-0198 (JP)
  - Medical & Biological Laboratories Co., Ltd. Nagayo-shi, Aichi 460-0002 (JP)

- (72) Inventors:
  - MIYAWAKI, Atsushi
     Wako-shi, Saitama 351-0198 (JP)
  - KARASAWA, Satoshi, Medical & Biol. Labs.Co.,Ltd. Ina-shi, Nagano 396-0002 (JP)
- (74) Representative: Sternagel, Fleischer, Godemeyer & Partner Patentanwälte, An den Gärten 7 51491 Overath (DE)

### (54) PIGMENT PROTEIN

- (57) An object of the present invention is to provide a novel chromoprotein derived from *Cnidopus japonicus*. The present invention provides a chromoprotein derived from *Cnidopus japonicus* having the following properties:
  - (1) the absorption maximum wavelength is 610 nm, and fluorescence is not emitted;
- (2) the molar absorption coefficient is 66,700 at 610 nm; and
- (3) the pH sensitivity of light-absorbing property is stable at between pH 4 and pH 10.

### Description

### **TECHNICAL FIELD**

[0001] The present invention relates to a novel chromoprotein. More specifically, the present invention relates to a novel chromoprotein derived from *Cnidopus japonicus*, and the use thereof.

### **BACKGROUND ART**

- 10 [0002] Green fluorescent protein (GFP) derived from Aequorea victoria, a jellyfish, has many purposes in biological systems. Recently, various GFP mutants have been produced based on the random mutagenesis and semi-rational mutagenesis, wherein a color is changed, a folding property is improved, luminance is enhanced, or pH sensitivity is modified. Fluorescent proteins such as GFP are fused with other proteins by gene recombinant technique, and monitoring of the expression and transportation of the fusion proteins is carried out.
- 15 [0003] One of the most commonly used types of GFP mutant is Yellow fluorescent protein (YFP). Among Aequoreaderived GFP mutants, YFP exhibits the fluorescence with the longest wavelength. The values ε and Φ of the majority of YEPs are 60,000 to 100,000 M<sup>-1</sup>cm<sup>-1</sup> and 0.6 to 0.8, respectively (Tsien, R. Y. (1998). Ann. Rev. Biochem. 67, 509-544). These values are comparable to those of the general fluorescent group (fluorescein, rhodamine, etc.). Accordingly, improvement of the absolute luminance of YFP is nearly approaching its limit.
- [0004] In addition, cyan fluorescent protein (CFP) is another example of the GFP mutant. Of this type of protein, ECFP (enhanced cyan fluorescent protein) has been known. Moreover, red fluorescent protein (RFP) has been isolated from sea anemone (*Discoma sp.*). Of this type of protein, DasRed has been known. Thus, 4 types of fluorescent proteins, that are, green fluorescent protein, yellow fluorescent protein, cyan fluorescent protein, and red fluorescent protein, have successively been developed. The range of the spectrum has significantly been expanded.

### DISCLOSURE OF THE INVENTION

25

4Ò

45

50

[0005] An object of the present invention is to provide a novel chromoprotein derived from *Cnidopus japonicus*.
[0006] The present inventors have conducted intensive studies directed towards achieving the aforementioned object. They have designed suitable primers based on information regarding the amino acid sequences of known fluorescent proteins. Using these primers, they have succeeded in the amplification and cloning of a gene encoding a novel chromoprotein from the cDNA library of *Cnidopus japonicus* exhibiting a green color. The present inventors have further analyzed the light-absorbing properties and pH sensitivity of the obtained chromoprotein derived from *Cnidopus japonicus*. The present invention has been completed based on these findings.

[0007] That is to say, the present invention provides a chromoprotein derived from *Cnidopus japonicus* having the following properties:

- (1) the absorption maximum wavelength is 610 nm, and fluorescence is not emitted;
- (2) the molar absorption coefficient is 66,700 at 610 nm; and
- (3) the pH sensitivity of light-absorbing property is stable at between pH 4 and pH 10.

[0008] In another aspect, the present invention provides a chromoprotein having either one of the following amino acid sequences:

- (a) the amino acid sequence shown in SEQ ID NO: 1; and
- (b) an amino acid sequence comprising a deletion, substitution and/or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1, and having light-absorbing properties.

[0009] In another aspect, the present invention provides a chromoprotein capable of emitting fluorescence, which has an amino acid sequence, wherein, with respect to the amino acid sequence shown in SEQ ID NO: 1, alanine as an amino acid residue at position 28 is substituted by glycine, glutamic acid as an amino acid residue at position 41 is substituted by methionine, cysteine as an amino acid residue at position 145 is substituted by serine, and threonine as an amino acid residue at position 158 is substituted by isoleucine.

[0010] In another aspect, the present invention provides:

a chromoprotein having an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by leucine with respect to the amino acid sequence shown in SEQ ID NO: 1;

a chromoprotein having an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is

substituted by methionine with respect to the amino acid sequence shown in SEQ ID NO: 1;

a chromoprotein having an amino acid sequence, wherein glutamic acid as an amino acid residue at position 41 is substituted by leucine, and phenylalanine as an amino acid residue at position 80 is substituted by glycine, with respect to the amino acid sequence shown in SEQ ID NO: 1;

a chromoprotein capable of emitting fluorescence, which has an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by phenylalanine with respect to the amino acid sequence shown in SEQ ID NO: 1;

a chromoprotein capable of emitting fluorescence, which has an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by histidine with respect to the amino acid sequence shown in SEQ ID NO: 1; and

a chromoprotein capable of emitting fluorescence, which has an amino acid sequence, wherein cysteine as an amino acid residue at position 26 is substituted by valine, cysteine as an amino acid residue at position 143 is substituted by serine, and proline as an amino acid residue at position 199 is substituted by leucine, with respect to the amino acid sequence shown in SEQ ID NO: 1.

[0011] In another aspect, the present invention provides DNA encoding the protein of the present invention.

[0012] In another aspect, the present invention provides either one of the following DNAs:

- (a) DNA encoding the amino acid sequence shown in SEQ ID NO: 1; and
- (b) DNA encoding an amino acid sequence, which comprises a deletion, substitution and/or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1, and has light-absorbing properties.

[0013] In another aspect, the present invention provides DNA having either one of the following nucleotide sequences:

- (a) the nucleotide sequence shown in SEQ ID NO: 2; and
- (b) a nucleotide sequence comprising a deletion, substitution and/or addition of one or several nucleotides with respect to the nucleotide sequence shown in SEQ ID NO: 2, and encoding a protein having light-absorbing properties.
- [0014] In another aspect, the present invention provides DNA having the nucleotide sequence shown in any one of SEQ ID NOS: 12, 14, 16, 18, 20, or 22.
- [0015] In another aspect, the present invention provides a recombinant vector having the DNA of the present invention.
- [0016] In another aspect, the present invention provides a transformant having the DNA or recombinant vector of the present invention.
- [0017] In another aspect, the present invention provides a fusion protein composed of the chromoprotein of the present invention and another protein.
- [0018] In another aspect, the present invention provides a method for analyzing a physiologically active substance, which is characterized in that the FRET (fluorescence resonance energy transfer) method is applied using the chromoprotein of the present invention as an acceptor protein.
- [0019] In another aspect, the present invention provides a light-absorbing reagent kit comprising the chromoprotein, DNA, recombinant vector, transformant, or fusion protein of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

[0020]

25

30

Figure 1 shows the results obtained by measuring the absorption spectrum of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention. The transverse axis indicates the wavelength of absorbed light, and the vertical axis indicates absorbance.

Figure 2 shows the pH sensitivity of the absorption spectrum of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention. The transverse axis indicates pH value, and the vertical axis indicates absorbance. 610 nm indicates the absorbance that is specific to the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention, and 277 nm indicates the absorbance (light absorption by aromatic amino acids) that is generally used as a quantitative amount of protein. In other words, it is shown that the amount of protein is constant at 277 nm, and the absorbance at 610 nm that is specific to the chromoprotein (KGr) derived from *Cnidopus* 

japonicus of the present invention hardly changes in the range between pH 4 and pH 10.

Figure 3 shows the fluorescence spectrum of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting A at position 28 by G, substituting E at position 41 by M, substituting C at position 145 by S, and substituting T at position 158 by I in the amino acid sequence of KGr). The transverse axis indicates wavelength, and the vertical axis indicates fluorescence intensity. The term "em" indicates a fluorescence spectrum, and the term "ex" indicates an excitation spectrum.

Figure 4 shows the absorption spectrum of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting Y at position 64 by L in the amino acid sequence of KGr). Figure 5 shows the absorption spectrum of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting Y at position 64 by M in the amino acid sequence of KGr). Figure 6 shows the absorption spectrum of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting E at position 41 by L and substituting F at position 80 by G in the amino acid sequence of KGr).

Figure 7 shows the fluorescence and excitation spectrums of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting Y at position 64 by F in the amino acid sequence of KGr).

Figure 8 shows the absorption spectrum of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting Y at position 64 by F in the amino acid sequence of KGr). Figure 9 shows the fluorescence and excitation spectrums of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting Y at position 64 by H in the amino acid sequence of KGr).

Figure 10 shows the absorption spectrum of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting Y at position 64 by H in the amino acid sequence of KGr). Figure 11 shows the fluorescence and excitation spectrums of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting C at position 26 by V, substituting C at position 143 by S, and substituting P at position 199 by L in the amino acid sequence of KGr).

Figure 12 shows the absorption spectrum of a mutant of the chromoprotein (KGr) derived from *Cnidopus japonicus* of the present invention (a mutant obtained by substituting C at position 26 by V, substituting C at position 143 by S, and substituting P at position 199 by L in the amino acid sequence of KGr).

### BEST MODE FOR CARRYING OUT THE INVENTION

[0021] The embodiments of the present invention will be described in detail below.

#### (1) Chromoprotein of the present invention

[0022] The chromoprotein of the present invention is characterized in that it is derived from *Cnidopus japonicus*, and has the following properties:

- (1) the absorption maximum wavelength is 610 nm, and fluorescence is not emitted;
- (2) the molar absorption coefficient is 66,700 at 610 nm; and
- (3) the pH sensitivity of light-absorbing property is stable at between pH 4 and pH 10.

[0023] Cnidopus japonicus is one type of sea anemone belonging to Anthozoa of Cnidaria. Among the types of sea anemone that can be seen in Japan, Cnidopus japonicus has the highest degree of color mutation. Its withers height is always low, and it has a large number of warts on the body wall thereof. It has approximately 200 short tentacles. A parent sea anemone discharges developed embryos from its oral part. The discharged embryos become attached to the body wall of the parent sea anemone. Thereafter, the embryos are further developed, and as a result, they become baby sea anemone. Thus, this sea anemone was named Komochi Isoginchaku (a Japanese name meaning "seed sea anemone"). This type of sea anemone is distributed in the intertidal zones on the rock coasts between Hokkaido and Boso Peninsula and also in the zones immediately below the intertidal zones.

[0024] It is to be noted that a chromoprotein having the aforementioned properties was isolated using *Cnidopus japonicus* as a starting material in the examples described later, but that the chromoprotein of the present invention may also be obtained from forms of sea anemone other than *Cnidopus japonicus* in some cases. Such a chromoprotein is also included in the scope of the present invention.

[0025] As described in the examples below, the chromoprotein of the present invention has an absorption maximum wavelength of 610 nm and does not emit fluorescence. In addition, the present chromoprotein has a molar absorption coefficient of 66,700 at 610 nm. The molar absorption coefficient represents the amount of absorbed photons per mole

10

15

20

25

35

of molecule. Since the chromoprotein of the present invention does not emit fluorescence, the chromoprotein of the present invention can be used: (1) as an acceptor molecule (energy receptor) in FRET; (2) in development of a system for converting the energy of applied light into energy other than the light; and (3) in introduction of a mutation into the amino acid sequence of the protein to modify it so that it emits fluorescence.

[0026] In addition, the chromoprotein of the present invention is characterized in that the pH sensitivity of light-absorbing properties is stable at between pH 4 and pH 10. That is to say, in the case of the chromoprotein of the present invention, the peak value of the absorption spectrum does not significantly fluctuate in the range between pH 4 and pH 10. Accordingly, even under the same conditions, the chromoprotein of the present invention can be used in a broad range of pH environments, and thus, the use of the chromoprotein *in vivo* has few restrictions.

[0027] The examples of the chromoprotein of the present invention include a chromoprotein having either one of the following amino acid sequences:

- (a) the amino acid sequence shown in SEQ ID NO: 1, and
- (b) an amino acid sequence comprising a deletion, substitution and/or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1, and having light-absorbing properties.

[0028] The scope of "one or several" in the phrase "an amino acid sequence comprising a deletion, substitution and/ or addition of one or several amino acids" is not particularly limited in the present specification. For example, it means 1 to 20, preferably 1 to 10, more preferably 1 to 7, further preferably 1 to 5, and particularly preferably 1 to 3.

[0029] The term "light-absorbing properties" is used in the present specification to mean properties capable of absorbing light having a certain wavelength. For example, an absorption maximum wavelength may be 610 nm as in the case of the chromoprotein described in the present specification, or the value of the absorption maximum wavelength may also be shifted. It is preferable that the pH sensitivity of light-absorbing properties is stable at between pH 4 and pH 10.

[0030] The chromoprotein of the present invention having the amino acid sequence shown in SEQ ID NO: 1 in the sequence listing does not emit fluorescence. In the present invention, one or several amino acids are deleted, substituted, and/or added with respect to the amino acid sequence shown in SEQ ID NO: 1, so as to produce a protein having modified light-absorbing properties, or so as to produce a protein emitting fluorescence in some cases. The thus produced proteins are also included in the scope of the present invention.

[0031] A specific example of a fluorescent protein produced by such mutation of amino acids may be a fluorescent protein having an amino acid sequence, wherein, with respect to the amino acid sequence shown in SEQ ID NO: 1, alanine as an amino acid residue at position 28 is substituted by glycine, glutamic acid as an amino acid residue at position 41 is substituted by methionine, cysteine as an amino acid residue at position 145 is substituted by serine, and threonine as an amino acid residue at position 158 is substituted by isoleucine.

[0032] Other specific examples of a fluorescent protein produced by such mutation of amino acids may include: a chromoprotein having an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by leucine with respect to the amino acid sequence shown in SEQ ID NO: 1; a chromoprotein having an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by methionine with respect to the amino acid sequence shown in SEQ ID NO: 1; a chromoprotein having an amino acid sequence, wherein glutamic acid as an amino acid residue at position 41 is substituted by leucine, and phenylalanine as an amino acid residue at position 80 is substituted by glycine, with respect to the amino acid sequence shown in SEQ ID NO: 1; a chromoprotein capable of emitting fluorescence, which has an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by phenylalanine with respect to the amino acid sequence shown in SEQ ID NO: 1; and a chromoprotein capable of emitting fluorescence, which has an amino acid sequence shown in SEQ ID NO: 1; and a chromoprotein capable of emitting fluorescence, which has an amino acid sequence, wherein cysteine as an amino acid residue at position 26 is substituted by valine, cysteine as an amino acid residue at position 143 is substituted by serine, and proline as an amino acid residue at position 199 is substituted by leucine, with respect to the amino acid sequence shown in SEQ ID NO: 1.

[0033] The method of obtaining the chromoprotein of the present invention is not particularly limited. The protein may be either a protein synthesized by chemosynthesis, or recombinant protein produced by a gene recombination technique.

[0034] Where a recombinant protein is produced, it is necessary to obtain DNA encoding the protein. Appropriate primers are designed by using information regarding the amino acid sequence shown in SEQ ID NO: 1 of the sequence listing of the present specification and the nucleotide sequence shown in SEQ ID NO: 2 thereof. Using these primers, PCR is carried out by using cDNA library derived from *Cnidopus japonicus* as a template, so that DNA encoding the chromoprotein of the present invention can be obtained. The chromoprotein of the present invention can be produced by introducing this DNA into an appropriate expression system. Expression in an expression system will be described

15

later in the present specification.

#### (2) DNA of the present invention

10

20

35

- [0035] According to the present invention, a gene encoding the chromoprotein of the present invention is provided.
  [0036] Specific examples of DNA encoding the chromoprotein of the present invention may include either one of the following DNAs:
  - (a) DNA encoding the amino acid sequence shown in SEQ ID NO: 1; and
  - (b) DNA encoding an amino acid sequence, which comprises a deletion, substitution and/or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1, and has light-absorbing properties.

[0037] Other examples of DNA encoding the chromoprotein of the present invention may include either one of the following DNAs:

- (a) the nucleotide sequence shown in SEQ ID NO: 2; and
- (b) a nucleotide sequence comprising a deletion, substitution and/or addition of one or several nucleotides with respect to the nucleotide sequence shown in SEQ ID NO: 2, and encoding a protein having light-absorbing properties.

[0038] Further, examples of the DNA having the nucleotide sequence comprising a deletion, substitution and/or addition of one or several nucleotides with respect to the nucleotide sequence shown in SEQ ID NO: 2, and encoding a protein having light-absorbing properties, may include DNA having the nucleotide sequence shown in any one of SEQ ID NOS: 12, 14, 16, 18, 20, or 22.

[0039] The DNA of the present invention can be synthesized by, for example, the phosphoamidite method, or it can also be produced by polymerase chain reaction (PCR) using specific primers. The DNA of the present invention is produced by the method described above in the specification.

[0040] A method of introducing a desired mutation into a certain nucleic acid sequence is known to a person skilled in the art. For example, known techniques such as a site-directed mutagenesis, PCR using degenerated oligonucle-otides, or the exposure of cells containing nucleic acid to mutagens or radioactive rays, are appropriately used, so as to construct DNA having a mutation. Such known techniques are described in, for example, Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY., 1989; and Current Protocols in Molecular Biology, Supplements 1 to 38, John Wiley & Sons (1987-1997).

### (3) Recombinant vector of the present invention

[0041] The DNA of the present invention can be inserted into a suitable vector and used. The type of a vector used in the present invention is not particularly limited. For example, it may be either a vector that can autonomously replicate (e.g., a plasmid, etc.), or vector that is incorporated into the genomes of host cells when it is introduced into the host cells and is then replicated together with the chromosome into which it is incorporated.

[0042] The vector used in the present invention is preferably an expression vector. In an expression vector, elements necessary for transcription (e.g., a promoter, etc.) are functionally ligated to the DNA of the present invention. The promoter is a DNA sequence which shows a transcriptional activity in host cells, and it is appropriately selected depending on the type of host cells.

[0043] Examples of a promoter which can operate in bacterial cells may include a *Bacillus stearothermophilus* maltogenic amylase gene promoter, a *Bacillus licheniformis* alpha-amylase gene promoter, a *Bacillus amyloliquefaciens* BAN amylase gene promoter, a *Bacillus subtilis* alkaline protease gene promoter, a *Bacillus pumilus* xylosidase gene promoter, P<sub>B</sub> and P<sub>L</sub> promoters of phage rhamda, and lac, trp and tac promoters of

#### Escherichia coli.

[0044] Examples of a promoter which can operate in mammalian cells may include an SV40 promoter, an MT-1 (metallothionein gene) promoter, and an adenovirus-2 major late promoter. Examples of a promoter which can operate in insect cells may include a polyhedrin promoter, a P10 promoter, an *Autographa californica* polyhedrosis basic protein promoter, a baculovirus immediate-early gene 1 promoter, and a baculovirus 39K delayed-early gene promoter. Examples of a promoter which can be operate in yeast host cells may include promoters derived from yeast glycolytic genes, an alcohol dehydrogenase gene promoter, a TPI1 promoter, and an ADH2-4c promoter.

[0045] Examples of a promoter which can operate in filamentous cells may include an ADH3 promoter and a tpiA promoter.

[0046] In addition, an appropriate terminator such as a human growth hormone terminator, or a TPI1 terminator or ADH3 terminator for fungal cells, may be functionally bound to the DNA of the present invention, as necessary. The recombinant vector of the present invention may further have elements such as a polyadenylation signal (e.g., one derived from SV40 or the adenovirus 5E1b region), a transcription enhancer sequence (e.g., an SV40 enhancer), or a translation enhancer sequence (e.g., one encoding the adenovirus VA RNA).

[0047] The recombinant vector of the present invention may further comprise a DNA sequence which enables the replication of the recombinant vector in host cells. SV40 replication origin is an example of such a sequence (when the host cells are mammalian cells).

[0048] The recombinant vector of the present invention may further comprise a selective marker. Examples of such a selective marker may include genes, complements of which are absent from host cells, such as a dihydrofolate reductase (DHFR) gene or a *Shizosaccharomyces pombe* TPI gene, and drug resistant genes such as ampicillin, kanamycin, tetracycline, chloramphenicol, neomycin or hygromycin-resistant genes.

[0049] A method for ligating the DNA of the present invention, a promoter and, as desired, a terminator and/or a secretory signal sequence to one another and inserting these items into a suitable vector is known to a person skilled in the art.

### (4) Transformant of the present invention

20

[0050] A transformant can be produced by introducing the DNA or recombinant vector of the present invention into a suitable host.

[0051] Any cell can be used as a host cell into which the DNA or recombinant vector of the present invention is introduced, as long as the DNA construct of the present invention can be expressed therein. Examples of such a cell may include bacteria, yeasts, fungal cells, and higher eukaryotic cells.

[0052] Examples of bacteria may include Gram-positive bacteria such as Bacillus or Streptomyces, and Gram-negative bacteria such as *Escherichia coli*. These bacteria may be transformed by the protoplast method or other known methods, using competent cells.

[0053] Examples of mammalian cells may include HEK 293 cells, HeLa cells, COS cells, BHK cells, CHL cells, and CHO cells. A method of transforming mammalian cells and expressing the introduced DNA sequence in the cells is also known. Examples of such a method may include the electroporation, the calcium phosphate method, and the lipofection method.

[0054] Examples of yeast cells may include those belonging to Saccharomyces or Shizosaccharomyces. Examples of such cells may include Saccharomyces cerevisiae and Saccharomyces kluyveri. Examples of a method of introducing a recombinant vector into yeast host cells may include the electroporation, the spheroplast method, and the lithium acetate method.

[0055] Examples of other fungal cells may include those belonging to *Filamentous fungi* such as Aspergillus, Neurospora, Fusarium or Trichoderma. Where *Filamentous fungi* are used as host cells, transformation can be carried out by incorporating DNA constructs into host chromosomes, so as to obtain recombinant host cells. Incorporation of DNA constructs into the host chromosomes is carried out by known methods, and such known methods may include homologous recombination and heterologous recombination.

[0056] Where insect cells are used as host cells, both a vector into which a recombinant gene is introduced and a baculovirus are co-introduced into insect cells, and a recombinant virus is obtained in the culture supernatant of the insect cells. Thereafter, insect cells are infected with the recombinant virus, so as to allow the cells to express proteins (described in, for example, Baculovirus Expression Vectors, A Laboratory Manual; and Current Protocols in Molecular Biology, Bio/Technology, 6, 47 (1988)).

[0057] The Autographa californica nuclear polyhedrosis virus, which is a virus infecting to insects belonging to Barathra brassicae, can be used as baculovirus.

[0058] Examples of insect cells used herein may include Sf9 and Sf21, which are *Spodoptera frugiperda* ovarian cells [Baculovirus Expression Vectors, A Laboratory Manual, W. H. Freeman & Company, New York, (1992)], and HiFive (manufactured by Invitrogen), which are *Trichoplusia ni* ovarian cells.

[0059] Examples of the method of co-introducing both a vector into which a recombinant gene has been introduced and the above baculovirus into insect cells to prepare a recombinant virus may include the calcium phosphate method and the lipofection method.

[0060] The above transformant is cultured in an appropriate nutritive medium under conditions enabling the introduced DNA construct to be expressed. In order to isolate and purify the protein of the present invention from the culture product of the transformant, common methods of isolating and purifying proteins may be used.

[0061] For example, where the protein of the present invention is expressed in a state dissolved in cells, after com-

pletion of the culture, cells are recovered by centrifugal separation, and the recovered cells are suspended in a water type buffer. Thereafter, the cells are disintegrated using an ultrasonic disintegrator or the like, so as to obtain a cell-free extract. A supernatant is obtained by centrifuging the cell-free extract, and then, a purified sample can be obtained from the supernatant by applying, singly or in combination, the following ordinary protein isolation and purification methods: the solvent extraction, the salting-out method using ammonium sulfate or the like, the desalting method, the precipitation method using an organic solvent, the anion exchange chromatography using resins such as Gethylaminoethyl (DEAE) sepharose, the cation exchange chromatography using resins such as S-Sepharose FF (manufactured by Pharmacia), the hydrophobic chromatography using resins such as butyl sepharose or phenyl sepharose, the gel filtration method using a molecular sieve, the affinity chromatography, the chromatofocusing method, and the electrophoresis such as isoelectric focusing.

### (5) Use of the chromoprotein of the present invention and a fusion protein comprising the same

[0062] The chromoprotein of the present invention can be fused with another protein, so as to construct a fusion protein. The type of said another protein to be fused to the chromoprotein of the present invention is not particularly limited, and preferred examples may include a protein which interacts with another molecule. The examples may include a receptor protein or ligand thereof, antigen, antibody and the like.

[0063] A method of obtaining the fusion protein of the present invention is not particularly limited. It may be either a protein synthesized by chemosynthesis, or recombinant protein produced by a gene recombination technique.

[0064] Where a recombinant fusion protein is produced, it is necessary to obtain DNA encoding the protein. The DNA encoding the chromoprotein of the present invention and the DNA encoding the another protein to be fused to the chromoprotein, can be obtained by the method as mentioned above in this specification or by the method similar to it. Then, these DNA fragments are ligated to one another by a gene recombination technique, so that DNA encoding the desired fusion protein can be obtained. This DNA is then introduced into an appropriate expression system, so that the fusion protein of the present invention can be produced.

[0065] FRET (fluorescence resonance energy transfer) has been known as a means for analyzing the interaction between molecules. In FRET, for example, a first molecule labeled with a cyan fluorescent protein (CFP) acting as a first fluorescent protein is allowed to coexist with a second molecule labeled with a yellow fluorescent protein (YFP) acting as a second fluorescent protein, so as to allow the yellow fluorescent protein (YFP) to act as an acceptor molecule and to allow the cyan fluorescent protein (CFP) to act as a donor molecule. Thus, FRET (fluorescence resonance energy transfer) is allowed to take place between both molecules, so as to visualize the interaction between the first and second molecules. Namely, in FRET, different dyes are introduced into two types of molecules. One dyes with a higher energy level (a donor molecule) is selectively excited, and the fluorescence of the dye is measured. Longwavelength fluorescence from the other dye (an acceptor molecule) is also measured. The interaction between the molecules is visualized by using the difference between the amounts of both fluorescences. Only when both dyes are adjacent to each other due to the interaction of the two types of molecules, a decrease in the fluorescence of the donor molecule and an increase in the fluorescence of the acceptor molecule are observed by single wavelength excitation dual wavelength photometry. However, in a case where a chromoprotein is used as an acceptor molecule, a decrease in the fluorescence of the donor molecule occurs only when both dyes are adjacent to each other by the interaction of the two types of molecules. Such a decrease can be observed by single wavelength excitation single wavelength photometry. Thus, the use of the chromoprotein of the present invention enables facilitation of measurement apparatuses.

[0066] The chromoprotein of the present invention is particularly advantageous when it is used as an acceptor molecule in FRET (fluorescence resonance energy transfer). That is to say, a fused form (a first fused form) of the chromoprotein of the present invention and a test substance is first produced. Then, a fused form (a second fused form) of another test substance interacting with the above test substance and another fluorescent protein is produced. Thereafter, the first fused form is allowed to interact with the second fused form, and the generated fluorescence is analyzed, so that the interaction between the aforementioned two types of test substances can be analyzed. FRET (fluorescence resonance energy transfer) using the chromoprotein of the present invention may be carried out either in a test tube or in a cell.

### (6) Kit of the present invention

[0067] The present invention provides a light-absorbing reagent kit comprising at least one which is selected from the chromoprotein, fusion protein, DNA, recombinant vector or transformant, which are described in the present specification. The kit of the present invention can be produced from commonly used materials that are known per se, by using common methods.

[0068] Reagents such as the chromoprotein or the DNA are dissolved in an appropriate solvent, so that the reagents

10

25

35

can be prepared in a form suitable for conservation. Water, ethanol, various types of buffer solution, etc. can be used as such a solvent.

[0069] The present invention will be further described in the following examples. However, the present invention is not limited by these examples.

**EXAMPLES** 

Example 1: Isolation of gene encoding novel chromoprotein from sea anemone

(1) Extraction of total RNA

[0070] A chromoprotein gene was isolated from sea anemone emitting a green color. Cnidopus japonicus emitting a green color was used as a material. Frozen Cnidopus japonicus was crushed in a mortar. 7.5 ml of "TRIzol" (GIBCO BRL) was added to 1 g (wet weight) of Cnidopus japonicus, and the mixture was homogenized, followed by centrifugation at 1,500  $\times$  g for 10 minutes. 1.5 ml of chloroform was added to the supernatant. The mixture was stirred for 15 seconds and then left at rest for 3 minutes. The resultant product was centrifuged at 7,500  $\times$  g for 15 minutes. 3.75 ml of isopropanol was added to the supernatant. The mixture was stirred for 15 seconds and then left at rest for 10 minutes. The resultant product was centrifuged at 17,000  $\times$  g for 10 minutes. The supernatant was discarded, and 6 ml of 70% ethanol was added thereto. The obtained mixture was centrifuged at 17,000  $\times$  g for 10 minutes. The supernatant was discarded, and the precipitate was dissolved in 200  $\mu$ l of DEPC water. Total RNA dissolved in the DEPC water was 100 times diluted, and the values of 0.0.260 and 0.0.280 were measured, so as to determine the concentration of RNA. 1.2 mg of the total RNA was obtained from a green individual.

(2) Synthesis of first stand cDNA

[0071] cDNA (33  $\mu$ I) was synthesized from 4  $\mu$ g of the total RNA using a kit for synthesizing first strand cDNA, "Ready To Go" (Amersham Pharmacia).

(3) Degenerated PCR

[0072] Using 3  $\mu$ l out of the synthesized first strand cDNA (33  $\mu$ l) as a template, PCR was carried out. Primers were designed and produced by comparing the amino acid sequences of known fluorescent proteins, extracting similar portions, and converting them into nucleotide sequences. The sequences of the used primers are shown below:

5'-GGIGSICCIHTISCITT-3' (primer 1) (SEQ ID NO: 3);

and

wherein I represents inosine, S represents C or G, and H represents A, T, or C.

Composition of PCR reaction s	solution
Template (first strand cDNA)	3 μΙ
X 10 taq buffer	5 μl ˙
2.5 mM dNTPs	4 ա
100 uM primer 3	1 μΙ
100 uM primer 4	1 μ1
Milli Q	35 µl
Taq polymerase (5 U/µl)	1 μ1

RCR reaction conditions 94°C, 1 minute (PAD) 94°C, 30 seconds (denaturation) 52°C, 30 seconds (annealing of the primers to the template) 72°C, 1 minute (elongation of the primers)

[0073] 30 cycles consisting of the above 3 steps were carried out. The annealing temperature was decreased 0.3°C per cycle. That is to say, the annealing temperature in the 30<sup>th</sup> cycle was 43°C. 72°C, 7 minutes (final elongation)

Retention at 4°C

[0074] Using 1  $\mu$ I of an amplified product obtained as a result of the first PCR reaction as a template, PCR was carried out once again under the same conditions. A 800-bp fragment (derived from the green individual) was cut out by agarose gel electrophoresis and then purified. This 800-bp fragment contained a 3'-UTR portion as a whole.

5 (4) Subcloning and sequencing

[0075] The purified DNA fragment was ligated to a pT7-blue vector (Novagen). Escherichia coli (TG1) was transformed with the vector, and the obtained transformants were subjected to blue white selection. Thereafter, plasmid DNA was purified from white colonies of Escherichia coli. The nucleotide sequence of the inserted DNA fragment was determined by a DNA sequencer. The obtained nucleotide sequence was compared with the nucleotide sequences of other fluorescent protein genes to confirm that the nucleotide sequence of the DNA was derived from a fluorescent protein. 5'-RACE and 3'-RACE methods were applied to a gene that had been confirmed to be a part of a fluorescent protein gene, so as to carry out the cloning of a full-length gene.

(5) 5'-RACE method

[0076] In order to determine the nucleotide sequence of the 5'-terminal side of the DNA fragment obtained by degenerated PCR, the 5'-RACE method was applied using 5'-RACE System for Rapid Amplification of cDNA Ends, Version 2.0 (GIBCO BRL).  $3 \mu g$  of the total RNA prepared in (1) above was used as a template.

[0077] For the first amplification of DC-tailed cDNA of the green individual, the following primers were used:

### 5'-GGCCACGCGTCGACTAGTACGGGIIGGGIIG-3' (primer 3) (SEO ID NO:

5);

and

### 5'-AGACGAGGCAATTTCCATCAAG-3' (primer 4) (SEQ ID NO: 6),

wherein I represents inosine.

[0078] For the second amplification, the following primers were used:

5'-GGCCACGCGTCGACTAGTAC-3' (primer 5) (SEQ ID NO: 7);

and

### 5'-GGCTACGCTTCCATATTGGCAGTT-3' (primer 6) (SEO ID NO: 8).

PCR reaction conditions and the like were determined in accordance with the protocols attached with the kit. [0079] The 350-bp amplified band was cut out by agarose gel electrophoresis and then purified. The purified DNA fragment was ligated to a pT7-blue vector (Novagen). Escherichia coli (TG1) was transformed with the vector, and the obtained transformants were subjected to blue white selection. Thereafter, plasmid DNA was purified from white colonies of Escherichia coli. The nucleotide sequence of the inserted DNA fragment was determined by a DNA sequencer. The entire nucleotide sequence is shown in SEQ ID NO: 2, and the entire amino acid sequence is shown in SEQ ID

NO: 1.

Example 2: Expression of protein in Escherichia coli

[0080] Primers corresponding to the N- and C-termini of the protein were produced from the obtained full-length nucleotide sequence. PCR was carried out using the primers and the first strand cDNA prepared in (2) above as a template. The used primers are as follows:

5'-CGGGATCCGACCATGGCTTCCAAAATCAGC-3' (primer 7) (SEQ ID NO: 9);

and

5'-CCGGAATTCTTAATTGTGACCAAGTTTAGATGGGCA-3' (primer 8) (SEQ ID NO: 10).

2Ó

10

15

Composition of PCR reaction so	Composition of PCR reaction solution								
Template (first strand cDNA)	3 µl								
X 10 pyrobest buffer	5 μΙ								
2.5 mM dNTPs	4 µі								
100 μM primer 7	1 μΙ								
100 μM primer 8	1 ա								
Milli Q	35 μί								
Pyrobest polymerase (5 U/μΙ)	் 1 ய								

30

RCR reaction conditions

94°C, 1 minute (PAD)

94°C, 30 seconds (denaturation)

55°C, 30 seconds (annealing of the primers to the template)

72°C, 1 minute (elongation of the primers)

[0081] 30 cycles consisting of the above 3 steps were carried out.

72°C, 7 minutes (final elongation)

Retention at 4°C

[0082] An amplified band of approximately 700 bp was cut out by agarose gel electrophoresis and then purified. The purified DNA fragment was subcloned into the *BamHI-EcoRI* site of a pRSET vector (Invitrogen), and it was then allowed to express in *Escherichia coli* (JM109-DE3). Since the expressed protein was constructed such that His-tag was attached to the N-terminus thereof, it was purified with Ni-Agarose gel (QIAGEN). Purification was carried out in accordance with the attached protocols.

Example 3: Analysis of protein

(1) Analysis of light-absorbing properties

[0083] The light-absorbing properties of the protein expressed in Example 2 were analyzed.

[0084] An absorption spectrum was measured using a 50 mM HEPES solution (pH 7.5) containing a 20  $\mu$ M chromoprotein. A molar absorption coefficient was calculated from the peak value of this spectrum. In the case of the chromoprotein derived from the green individual (referred to as KGr), the absorption peak was observed at 610 nm, and no fluorescence was detected (Table 1, Figure 1).

55

45

#### Table 1

Properties of chi	romoprotein (KGr)				
Absorption maximum	Fluorescence maximum	Molar absorption coefficient	quantum yield	pH sensitivity	Number of amino acids
610 nm		66,700 (610 nm)	•	Non	232

### (1) Measurement of pH sensitivity

The pH sensitivity of the protein expressed in Example 2 was analyzed.

The absorption spectrum of the protein was measured in the following 100 mM buffer solution (Figure 2). The following buffer solutions were used for each pH:

pH 4 and 5: Acetate buffer pH 6: MES buffer pH 7 and 8: HEPES buffer pH 9 and 10: Glycine buffer

The peak value did not significantly change at any pH.

Example 4: Modification of KGr

15

20

25

30

[0085] In KGr, A at position 28 was substituted by G, E at position 41 was substituted by M, C at position 145 was substituted by S, and T at position 158 was substituted by I, so that the KGr was modified to have an absorption peak at 444 nm and to emit yellow fluorescence with a peak at 534 nm (Figure 3).

Example 5: Modification of properties of KGr by amino acid substitution

[0086] Y at position 64 that is a chromophore-forming amino acid (QYG) of KGr was substituted by L or M, so that the absorption peak became 418 nm and so that the absorption peak was shifted from the original absorption peak at 610 nm to the shorter wavelength side (Figures 1 and 2). The amino acid sequence of the protein wherein Y at position 64 was substituted by L is shown in SEQ ID NO: 11, and the nucleotide sequence thereof is shown in SEQ ID NO: 13, and the nucleotide sequence thereof is shown in SEQ ID NO: 13, and the nucleotide sequence thereof is shown in SEQ ID NO: 14.

[0087] E at position 41 was substituted by L, and F at position 80 was substituted by G, so that the absorption peak become 528 nm and so that the absorption peak was shifted from the original absorption peak at 610 nm to the shorter wavelength side (Figure 3). The amino acid sequence of this protein is shown in SEQ ID NO: 15, and the nucleotide sequence thereof is shown in SEQ ID NO: 16.

[0088] Y at position 64 that is a chromophore-forming amino acid (QYG) was substituted by F, so that the absorption peak became 412 nm, and so that the absorption peak was shifted from the original absorption peak at 610 nm to the shorter wavelength side and the protein was further modified to emit fluorescence with a peak at 504 nm (Figures 4 and 5). The amino acid sequence of this protein is shown in SEQ ID NO: 17, and the nucleotide sequence thereof is shown in SEQ ID NO: 18.

[0089] Y at position 64 that is a chromophore-forming amino acid (QYG) was substituted by H, so that the absorption peak became 418 nm, and so that the absorption peak was shifted from the original absorption peak at 610 nm to the shorter wavelength side and the protein was further modified to emit fluorescence with a peak at 520 nm (Figures 6 and 7). The amino acid sequence of this protein is shown in SEQ ID NO: 19, and the nucleotide sequence thereof is shown in SEQ ID NO: 20.

[0090] C at position 26 was substituted by V, C at position 143 was substituted by S, and P at position 199 was substituted by L, so that the absorption peak became 585 nm, and so that the absorption peak was shifted from the original absorption peak at 610 nm to the shorter wavelength side and the protein was further modified to emit fluorescence with a peak at 625 nm. This fluorescent protein was defined as KGr Rb (Figures 8 and 9). The amino acid sequence of this protein is shown in SEQ ID NO: 21, and the nucleotide sequence thereof is shown in SEQ ID NO: 22.

### INDUSTRIAL APPLICABILITY

[0091] The present invention provides a novel chromoprotein derived from Cnidopus japonicus. The chromoprotein

of the present invention has desired fluorescence properties and low pH sensitivity. Thus, it is useful for molecular biology analysis.

13

**55** 

15

	SEC	UENC	E LI	STIN	G				•							
_	<11	.0> R	IKEN	į					٠.							
5	<12	20> C	hrom	o pr	otei	n							. :			
	<13	0> A	3134	7A	*											
10	<16	io> 2	2		•								•			
	•		•											•		
	<21	0> 1							•							
·	<21	1> 2	32				•									
	<21	2> P	RT	•												
	<21	3> C	nido	pus	japo	nicu	s		·.				•			
	<40	0> 1		•												
25	Met	Ala	Ser	Lys	Ile	Ser	Asp	Asn	Val	Arg	Ile	Lys	Leu	Tyr	Met	Glu
	1		·		. 5		-			10					15	
3 <b>0</b>	Gly	Thr	Val	Asn	Asn	His	His	Phe	Met	Cys	Glu	Ala	Glu	Gly	Glu	Gly
				20					25					. 30		
	Lys	Pro	Tyr	Glu	Gly	Thr	Gln	Met	Glu	Asn	Ile	Lys	Val	Thr	Lys	Gly
			35					40					45			
•	Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Tyr
o		50					55					60	:			
	Gly	Ser	Val	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe
	65				٠.	70					75			٠		80
5	Lys	Gln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr
				•	85			•		90					95	
<b>o</b>	Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly
				100		. ,			105					110		
5	Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro
-	•		115			٠.		120	<i>:</i> ·				125			

	Asn Gly Pr	ro Val Met	Gln Ly	ys Lys	Thr Gln	Gly Trp	Glu Pro	Cys Cys	
	130		13	35		140			
<i>5</i>	Glu Met Ar	rg Tyr Thr	Arg As	sp Gly	Val Leu	Cys Gly	Gln Thr	Leu Met	
	145		150			155		160	
10	Ala Leu Ly	ys Cys Ala	Asp G	ly Asn	His Leu	Thr Cys	His Leu	Arg Thr	
		165			170			175	
15	Thr Tyr Ar	rg Ser Lys	Lys Al	la Ala	Lys Ala	Leu Gln	Met Pro	Pro Phe	
•		180			185		190		
	His Phe Se	er Asp His	Arg Pr	ro Glu	Ile Val	Lys Val	Ser Glu	Asn Gly	
20	19	95		200			205		
	Thr Leu Ph	ne Glu Gln	His G	lu Ser	Ser Val	Ala Arg	Tyr Cys	Gln Thr	
25	210		21	15		220			
	Cys Pro Se	er Lys Leu	Gly Hi	is Asn					•
	225		230						
30									
	⟨210⟩ 2	•	· .	•		٠.		`	
35	<211> 699					. • •			
•	<212> DNA							· ·	4
40	<213> Cnic	dopus japo	nicus		• •				٠.
	<400>. 2								
	atg gct to	cc aaa atc	agc ga	ac aat.	gta cgt	atc aag	tta tat	atg gag	48
45	Met Ala Se	er Lys Ile	Ser As	sp Asn	Val Arg	Ile Lys	Leu Tyr	Met Glu	
	1		i		10		٠.	15	
50	ggc aca gt	tc aac aat	cat ca	ac ttc	atg tgc	gaa gct	gaa gga	gag ggc	96
	Gly Thr Va	al Asn Asn	His Hi	is Phe	Met Cys	Glu Ala	Glu Gly	Glu Gly	
	*	20			25	. :	30		
55	aag cca ta	ac gag gga	act ca	aa atg	gag aac	ata aaa	gtc acc	aaa gga	144
		,							

		Lys	Pro	Tyr	Glu	Gly	Thr	Gln	Met	Glu	Aśn	Ile	Lys	Val	Thr	Lys	Gly	
<b>5</b>				35					40	•				45				
		ggc	cct	ctg	ccg	ttc	tct	ttt	gat	atc	ttg	acg	cct	aac	tgc	caa	tat	192
		Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Tyr	•
10			50		•			55					60					
		gga	agc	gta	gcc	ata	acc	aag	tat	aca	tca	ggg	att	cca	gac	tac	ttt	240
15		Gly	Ser	Val	Ala	Ile	Thr	Lys	Тут	Thr	Ser	Gly	Ile	Pro	Asp	Туг	Phe	
		65					70					75			· · ·	•	80	•
20		aag	caa	tct	ttt	cct	gaą	gga	ttt	acc	tgg	gaa	aga	acc	aca	atc	tac	288
		Lys	Gln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr	
•	•					85			٠		90			,		95		
25	. •				gct											, i		336
		Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	•	Gln	Glu	Thr	Lys	Leu	Asp	Gly	
30					100			٠		105	٠				110			
	-				gtc													384
		Asn	Cys	٠.	Val	ıyr	ASN	TIE		He	Leu	Gly	Cys		Phe	Pro	Pro	
35	,	aat	aat	115	ata	ota.			120		•••	.,	•	125				400
					gtg Val	•			-									432
40		1.5	130			MC C		135	<i>D</i> , 3		OIN	01)	140	Olu	ιήο	Cys	Cys	
		gag		CEC	tat	aca	cgt		ggt	gtg	cta	tet		caa	aca	tta	atø	480
45	٠.				Tyr							٠.						100
		145					150	-	•			155	,				160	
		gca	ctt	aaa	tgc	gcc	gat.	ggg	aac	cac	ctc		tgc	cat	ctg	aga		528
50		•			Cys											. J		
						165					170					175		
55		act	tac	agġ	tcc	aaa	aag	gca	gca	aag	gcg	ttg	cag	atg	cca	ccc	ttc	576
						*											•	•

•	Thr Tyr Arg Ser Lys Lys Ala Ala Lys Ala Leu Gln Met Pro Pro Phe
.5	180 185 190
	cat ttt tca gac cat cgt cct gaa ata gtg aag gtt tca gag aac ggc 624
	His Phe Ser Asp His Arg Pro Glu Ile Val Lys Val Ser Glu Asn Gly
10	195 200 205
	aca cta ttt gaa cag cac gaa agt tca gtg gcc agg tac tgt caa aca 672
15	Thr Leu Phe Glu Gln His Glu Ser Ser Val Ala Arg Tyr Cys Gln Thr
	210 215 220
	tgc cca tct aaa ctt ggt cac aat taa 699
20	Cys Pro Ser Lys Leu Gly His Asn
	225 230
25	
	<210> 3
	<211> 17
30	<212> DNA
	<213> Artificial Sequence
35	<220>
	<223> Description of Artificial Sequence: Synthetic DNA
	<400> 3
40	ggigsiccih tiscitt 17
45	⟨210⟩ 4
	<211> 44
	<212> DNA
50	<213> Artificial Sequence
	⟨220⟩
55	<223> Description of Artificial Sequence: Synthetic DNA

	<400> 4
5	aactggaaga attcgcggcc gcagaatttt ttttttttt tttt
	<210> 5
o	⟨211⟩ 36
	(212> DNA
<i>5</i>	<213> Artificial Sequence
	⟨220⟩
	(223) Description of Artificial Sequence: Synthetic DNA
	<400> 5
	ggccacgcgt cgactagtac gggiigggii gggiig 36
5	
	<210> 6
	<211> 22
0	<212> DNA
	<213> Artificial Sequence
5	⟨220⟩
	<223> Description of Artificial Sequence: Synthetic DNA
0	<400> 6
	agacgaggca atttccatca ag 22
5	<210> 7
	<211> 20
9	<212> DNA
•	<213> Artificial Sequence
	⟨220⟩
5	<223> Description of Artificial Sequence: Synthetic DNA

	(400) /		٠٠.
5	ggccacgcgt cgactagtac	20	
	⟨210⟩ 8		
10	⟨211⟩ 24		
	<212> DNA		
15	<213> Artificial Sequence		
	⟨220⟩		
	<pre>&lt;223&gt; Description of Artificial Sequence:</pre>	Synthetic	DNA
20	⟨400⟩ 8		
	ggctacgctt ccatattggc agtt	24	
25			
	⟨210⟩ 9		. •
20	⟨211⟩ 30		
30	<212> DNA		
	<213> Artificial Sequence		
35	⟨220⟩		
	<pre>&lt;223&gt; Description of Artificial Sequence:</pre>	Synthetic	DNA
40	<400> 9		
	cgggatccga ccatggcttc caaaatcagc	30	
45	<210> 10		
	<211> 36		
50	<212> DNA		•
	<213> Artificial Sequence		
	⟨220⟩		
55	<pre>&lt;223&gt; Description of Artificial Sequence:</pre>	Synthetic I	DNA

,		<40	0> 1	0									.:		*		
5		ccg	gaat	tct	taat	tgtg	ac c	aagt	ttag	a tg	ggca			36			
		<210	0> 1	1													
10		<21	1> 2	32 .													
		<212	2> P	RT			٠							٠			
15		<213	3> C	nido	pus ,	japo	nicu	s									
		<400	)> 1	1									*				
		Met	Ala	Ser	Lys	Ile	Ser	Asp	Asn	Val	Arg	Ile	Lys	Leu	Tyr	Met	Glu
<i>2</i> 0		1				- 5					10					15	
	•	Gly	Thr	Val	Asn	Asn	His	His	Phe	Met	Cys	Ġlu	Ala	Glu	Gly	Glu	Gly
25					20					25					30		
	•	Lys	Pro	Tyr	Glu	Gly	Thr	Ģln	Met	Glu	Asn	Ile	Lys	Val	Thr	Lys	Gly
				35	. •		٠.		40					45			
<b>30</b>		Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Çys	Gln	Leu
		·	50			•	:	55					60				
35		Gly	Ser	Val	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe
		65	•				70					75					80
40 ·	٠.	Lys	Gln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Årg	Thr	Thr	Ile	Tyr
•					:	85				, :	90			-		95	
		Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	G1.y
45					100					105					110		
•		Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Așn	Phe	Pro	Pro
50				115					120					125			
		Asn	Gly	Pro	Val	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys
			130					135		٠			144			*	
55	. (	Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met

	145	150		155	160
· 5	Ala Leu Lys C	Cys Ala Asp	Gly Asn His L	eu Thr Cys His Leu	Arg Thr
	•	165	1	70	175
•	Thr Tyr Arg S	Ser Lys Lys	Ala Ala Lys A	la Leu Gln Met Pro	Pro Phe
10	1	.80	185	190	· ·
	His Phe Ser A	sp His Arg	Pro Glu Ile V	al Lys Val Ser Glu	Asn Gly
15	195		200	205	
	Thr Leu Phe G	Slu Gln His	Glu Ser Ser V	al Ala Arg Tyr Cys	Gln Thr
	210		215	220	
20	Cys Pro Ser L	ys Leu Gly	His Asn		
	225	230			
25	•				
,	<210> 12		•		
-	<211> 699				
30	<212> DNA				
	<213> Cnidopu	s japonicus	<b>S</b>		
35	<400> 12				
	atg gct tcc a	aa atc agc	gac aat gta c	gt atc aag tta tat	atg gag 48
40	Met Ala Ser L	ys Ile Ser	Asp Asn Val A	rg Ile Lys Leu Tyr	Met Glu
	1	5		10	15
	ggc aca gtc a	ac aat cat	cac ttc atg t	gc gaa gct gaa gga	gag ggc 96
45	Gly Thr Val A	sn Asn His	His Phe Met C	ys Glu Ala Glu Gly	Glu Gly
		20	25	30	
50	aag cca tac g	ag gga act	caa atg gag a	ac ata aaa gtc acc	aaa gga 144
2.1	Lys Pro Tyr G	lu Gly Thr	Gln Met Glu A	sn Ile Lys Val Thr	Lys Gly
	35		40	45	: •
55	ggc cct ctg c	cg ttc tct	ttt gat atc t	tg acg cct aac tgc	caa ctt 192
	the second secon				

•	Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Leu	•
5		50					55		٠.			60					
	gga	agc	gta	gcc	ata	acc	aag	tat	aca	tca	ggg	att	cca	gac	tac	ttt	240
٠	Gly	Ser	Val	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe	
10	65					70					75			•		80	
	aag	caa	tct	ttt	cct	gaa	gga	ttt	acc	tgg	gaa	aga	acc	aca	atc	tac	288
15	Lys	Gĺn	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr	
•			•		85			÷		90					95		
	gaa	gat	ggg	gct	tac	ctt	aca	act	caa	caa	ssg	acc	ass	ctt	gat	gga	336
20	Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly	
	,			100			•	·	105	•				110			
25	aat	tgc	ctc	gtc	tac	aat	att	aaa	atc	ctt	gga	tgt	aat	ttt	ccc	ссс	384
	Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro	
<i>30</i>			115					120				•	125				
		ggt							* .								432
	Asn	Gly	Pro	Val	Met	Gln		Lys	Thr	Gln	Gly		Glu	Pro	Cys	Cys	
35		130		,			135	٠,٠		. `		144			٠.		
		atg						_	٠			,					480
40		Met	Arg	iyr	ınr .		Asp	GIA	vai	Leu		GIÀ	Gin	ihr	Leu		
	145	-44		+		150	~~~				155					160	Eno
45		ctt	•													٠.	9 <i>2</i> 0
	Ala	Leu	Lys	Cys	165	изр	gry	VOII	1112	170°	11111	Cys	1115	Leu	175	1111	
	act	tac	200	tee		220	era.	ora.	220		ttä	rag.	atσ	cca		tto	576
50		Tyr											:	٠.,	-	٠. ٠	0.0
		.,.		180	2,0	2,0		-	185				,,,,,,	190		1110	2
55	cat	ttt	tca		cat	cgt	cct.	gaa		gtø	aag	gtt	tca		aac	ggc	624
		•			•	<u>.</u>				U-0	0	5- <b>-</b> ,	<del>-</del>	U-0			1

	His Phe	Ser Asp	His Arg	g Pro	Glu	Ile	Val	Lys	Val	Ser	Glu	Asn	Gly	
		195			200	• •				205				
5	aca cta	ttt gaa	cag cad	gaa	agt	tca	gtg	gcc	agg	tac	tgt	caa	aca	672
	Thr Leu	Phe Glu	Gln His	Glu	Ser	Ser	Val	Ala	Arg	Tyr	Cys	Gln	Thr	
10	210			215					220					
	tgc cca	tct aaa	ctt ggt	cac	aat	taa						•		699
15	Cys Pro	Ser Lys	Leu Gly	His	Asn									
	225		230	)						•				
			•					٠.	. ,					
20	<210> 13	3 ·						,			•			
	<211> 23	32						•		•			٠	•
25	<212> PI	RT												
	<213> Cr	nidopus	japonicu	ıs										
	<400> 13	3			•								٠.	
30	Met Ala	Ser Lys	Ile Ser	- Asp	Asn	Val	Arg	Ile	Lys	Leu	Tyr	Met	Glu	
•	1		5				10					15		•
<b>35</b> .	Gly Thr	Val Asn	Asn His	s His	Phe	Met	Cys	Glu	Ala	Glu	Gly	Glu	Gly	
	•	20				25	. :				30	•		
40	Lys Pro	Tyr Glu	Gly Thi	Gln	Met	Glu	Asn	Ile	Lys	Val	Thr	Lys	Gly	٠.
		35		٠.	40		-			45				
•	Gly Pro	Leu Pro	Phe Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Met	
45	50			55	:	٠.			60					
• •	Gly Ser	Val Ala	Ile Thi	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe	•
50	65		70	) .				75		-			80	
	Lys Gln	Ser Phe	Pro Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr	
			85				90			٠		95		
55	Glu Asp	Glÿ Ala	Tyr Lev	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly	

					100					105					110	١.		
5		Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro	
				115					120					125		٠		
	•	Asn	Gly	Pro	Val	Met	Ģln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys	
10			130		•			135	:				140					
		Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met	
15		145					150					155					160	
		Ala	Leu	Lys	Cys	Ala	Asp	Gly	Asn	His	Leu	Thr	Cys	His	Leu	Arg	Thr	
				-		165			•		170		•			175		
20		Thr	Tyr	Arg	Ser	Lys	Lys	Ala	Ala	Lys	Ala	Leu	Gln	Met	Pro	Pro	Phe	
	٠.				180					185					190			
25	•	His	Phe	Ser	Asp	His	Arg	Pro	Glu	Ile	Val	Lys	Val	Ser	Glu	Asn	Gly	
	N.			195					200		• •			205			•	
30		Thr	Leu	Phe	Glu	Gln	His	Glu	Ser	Ser	Val	Ala	Arg	Tyr	Cys	Gln	Thr	
		-	210					215					220					
· ·.		Cys	Pro	Ser	Lys	Leu	Gly	His	Asn	-						•	•	
35		225					230			-								
							•			•	1							
40			0> 14															
•			1> 69			•		-										
45			2> DN					•					:					
			3> Cr		ous .	japor	nicus	5										
			0> 14															,
50	•									gta								48
	•		Ala	Ser	Lys	Ile	Ser	Asp	Asn	Val		Ile	Lys	Leu	Tyr	Met	Glu	
55		. 1	٠			5	•				10				-	15	•	
		ggc	aca	gtc	aac	aat	cat	cac	ttc	atg	tgc	gaa	gct	gaa	gga	gag	ggc	96

		Gly	Thr	Val	Asn	Asn	His	His	Phe	Met	Cys	Glu	Ala	Glu	Gly	Glu.	Gly	
5					20					25					30			
		aag	cca	tac	gag	gga	act	caa	atg	gag	aac	ata	aaa	gtc	acc	aaa	gga	144
10		Lys	Pro	Tyr	Glu	Gly	Thr	Gln	Met	Glu	Asn	Ile	Lys	Val	Thr	Lys	Gly	
10			•	35				•	40		•			45				•
•		ggc	cct	ctg	ccg	ttc	tct	ttt	gat	atc	ttg	acg	cct	aac	tgc	caa	atg	192
15		Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Met	
			50					55					60		٠			•
20		gga	agc	gta	gcc	ata	acc	aag	tat	aca	tca	ggg	att	cca	gac	tac	ttt	240
		Gly	Ser	Val	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe	
		65					70					75		•	٠.		80	
25		aag	caa	tct	ttt	cct	gaa	gga	ttt	acc	tgg	gaa	aga	acc	aca	atc	tac	288
· .		Lys	Gln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr	
30	•	•				85					90				•	95		
		gaa	gat	ggg	gct	tac	ctt	aca	act	caa	caa	gaa	acc	aaa	ctt	gat	gga	336
<i>35</i>		Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly	
	•				100	,	ž.			105					110			
			1.1.	٠.				-			•					• • •		384.
40		Asn	Cys		Val	Tyr	Asn	Ile		Ile	Leu	Gly	Cys		Phe	Pro	Pro	
•				115					120					125				
45				٠.		•	•							•				432
		Asn		Pro	Val	Met	GIn		Lys	Thr	Gin		٠.		.Pro	Cys	Cys	
	· . : · · ·		130					135					140					
50	•			•				*.	•									480
		Glu	Met	Arg	lyr		٠, ٠	Asp	Gly	Val			Gly	Gln	Thr	Leu		•
55		145					150	٠				155					160	
		gca	ctt	aaa	tgc	gcc	gat	ggg	aac	cac	ctc	act	tgc	cat	ctg	aga	act	528

		Ala	Leu	Lys	Cys	Ala	Asp	Gly	Asn	His	Leu	Thr	Cys	His	Leu	Arg	Thr	
						165	•			••	170		•			175		
5		act	tac	agg	tcc	aaa	aag	gca	gca	aag	gcg	ttg	cag	atg	cca	ccc	ttc	576
-		Thr	Tyr	Arg	Ser	Lys	Lys	Ala	Ala	Lys	Ala	Leu	Gln	Met	Pro	Pro	Phe	
10					180					185					190		•	
		cat	ttt	tca	gac	cat	cgt	cct	gaa	ata	gtg	aag	gtt	tca	gag	aac	ggc	624
15		His	Phe	Ser	Asp	His	Arg	Pro	Glu	Ile	Val	Lys	Val	Ser	Glu	Asn	Gly	
				195					200					205				
	*.	aca	cta	ttt	gaa	cag	cac	gas	agt	tca	gtg	gcc	agg	tac	tgt	саа	aca	672
20	•	Thr	Leu	Phe	Glu	Gln	His	Glu	Ser	Ser	Val	Ala	Arg	Tyr	Cys	Gln	Thr	
			210					215	· :			•	220					
25		tgc	сса	tct	aaa	ctt	ggt	cac	aat	taa		•						699
		Cys	Pro	Ser	Lys	Leu	Gly	His.	Asn									- •
30		225	: '				230	٠٠.					•					. ·
50							,							-				
	· · ·	<210	)> 15	5	•							٠			•			
35		<21	L> 23	32							٠.							
		<212	2> PI	RT														
40				nidoj	ous .	japoı	nicus	5							: .			
		<400	)> 19	5						· · ·					٠.			. •
		Met	Ala	Ser	Lys		Ser	Asp	Asn	Val	:	Ile	Lys	Leu	Tyr	Met	Glu	
45 .	. •	1				5					10					15		
		Gly	Thr	Val		Asn	His	His	Phe		Cys	Glu	Ala	Glu		Glu	Gly	
50	÷.				20					25					30			
	•	Lys	Pro		Glu	Gly	Thr	Gln		Leu	Asn	Ile	Lys		Thr	Lys	Gly	
55				. 35		_:			40		_			45				
رد		Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Met	

			50				•	55					60				
_		Gly	Ser	Val	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Gly
5		65				٠	70					75					80
		Lys	Gln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr
10						85					90			-		95	
		Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly
15					100			,		105					110		
	<del></del>	Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro
	:			115				•	120					125			
20		Asn	Gly	Pro	Val	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys
			130				•	135					140		•		
25		Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met
- ,		145					150			-	. ·	155	٠.			٠.	160
30		Ala	Leu	Lys	Cys	Ala	Asp	Gly	Asn	His	Leu	Thr	Cys	His	Leu	Arg	Thr
-		•				165					170					175	
		Thr	Tyr	Arg	Ser	Lys	Lys	Ala	Ala	Lys	Ala	Leu	Gln	Met	Pro	Pro	Phe
35	•	•	•.		180	:		÷		185					190		
		His	Phe	Ser	Asp	His	Arg	Pro	Glu	Ile	Val	Lys	Val	Ser	Glu	Asn	Gly
40				195			٠		200				•	205			
		Thr	Leu	Phe	Glu	Gln	His	Glu	Ser	Ser	Val	Ala	Arg	Tyr	Cys	Gln	Thr
			210			Ť		215			·		220				
45	•	-	Pro	Ser	Lys	Leu		His	Asn			٠,			· ·		
		225					230			*							
50		-				•							•				
			0> 10								• •						
55	-		1> 69		÷		•								٠		
		<212	2> D!	NA .		•	•			•			•				

	<21	3> C	nido	pus	japo	nicu	s <sub>.</sub>										
ī	<40	0> 1	6	•					٠.								,
•	atg	gct	tcc	aaa	atc	agc	gac	aat	gta	cgt	atc	aag	tta	tat	atg	ctg	48
•	Met	Ala	Ser	Lys	Ile	Ser	Asp	Asn	Val	Arg	Ile	Lys	Leu	Tyr	Met	Glu	
<b>0</b>	1				5				•	10					. 15		
	ggc	aca	gtc	aac	aat	cat	cac	ttc	atg	tgc	gaa	gct	gaa	gga	gag	ggc	96
5	Gly	Thr	Val	Asn	Asn	His	His	Phe	Met	Cys	Glu	Ala	Glu	Gly	Glu	Gly	
			·	20					25					30			
•	aag	cca	tac	gag	gga	act	caa	atg	ctt	aac	ata	aaa	gto	acc	aaa	gga	144
υ 	Lys	Pro	Tyr	Glu	Gly	Thr	Gln	Met	Leu	Asn	Ile	Lys	Val	Thr	Lys	Gly	
			35					40					45				
5	ggc	cct	ctg	ccg	ttc	tct	ttt	gat	atc	ttg	acg	cct	aac	tgc	caa	tat	192
	Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Met	
0		50					55					60			_	٠.	
	gga	agc	gta	gcc	ata	acc	aag	tat	aca	tca	ggg	att	cca	gac	tac	ggt	240
	Gly	Ser	Val	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gl y	Ile	Pro	Asp	Tyr	Gly	
5	65		•			70		٠.	٠		<b>7</b> 5					80	٠.
	aag	caa	tct	ttt	cct	gaa	gga	ttt	acc	tgg	gaa	aga	acc	aca	atc	tac	288
o	Lys	G1n	Ser	Phe	Pro	G1u	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr	
		· .			85	•		:	٠	90				•	95	•	•
	gaa	gat	ggg	gct	tac	ctt	aca	act	caa	caa	gaa	acc	aaa	ctt	gat	gga	336
5	Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly	
			•	100	٠				105					110			
0	aat	tgc	ctc	gtc	tac	aat	att	aaa	atc	ctt	gga	tgt	aat	ttt	ccc	ccc	384
	. Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro	
			115	٠	•	٠		120				• .•	125		ż		
<i>5</i> 	aat	ggt	cct	gtg	atg	cag	aag	aaa	acc	caa	ggc	tgg	gaa	ccc	tgt	tgc	432

	•								٠.								
	Asn	Gly	Pro	Val	Met	G1n	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys	•
5	•	130					135		٠.	٠		140					
	gag	atg	cgc	tat	aca	cgt	gat	ggt	gtg	cta	tgt	ggc	caa	aca	tta	atg	480
	Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	G1n	Thr	Leu	Met	
10	145	•	•			150				-	155				1.	160	
	gca	ctt	aaa	tgc	gcc	gat	ggg	aac	cac	ctc	act	tgc	cat	ctg	aga	act	528
	Ala	Leu	Lys	Cys	Ala	Asp	Gly	Asn	His	Leu	Thr	Cys	His	Leu	Arg	Thr	
15					165		-		-	170					175		
	act	tac	agg	tec	aaa	aag	gca	gca	aag	gcg	ttg	cag	atg	cca		ttc	576
20	•									Ala							
				180					185					190			
oe.	cat	ttt	tca		cat	cgt	cct	gaa		gtg	aag	gtt			aac	ggc	624
25										Val		•					
			195					200			-,-		205			,	•
30	aca			gaa	cag	cac	gaa		tca	et.e	PCC	200		tet	caa	aca	672
• •										Val							012
<i>35</i>		210					215			7		220	- , _	0,0	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	12	
	tec		tct	aaa	ctt	ggt		aat	taa					i.		•	699
		•	. •		Leu											-	033
40	225		ĢŪI	5,5	200	230	1.10	1,511									
	220		•	·	*	200	-								•		
<b>45</b>	<b>/</b> 210	)> 1	7		:												
		1> 2:					•			-							
		2> PI				:			-	•					-		:
50					ian	.i.e			* .								· · .
				pus .	japoi	nicus	S		٠					٠.	• • •	·	
. 55		)> 11		•		•						•					
	Met	Ala	Ser	Lys	TIE	2er	Asp	Asn	Val	Arg.	lle	Lys	Leu	Tyr	Met	Glu	

	•					. 5					10					15	
5		Gly	Thr	Val	Asn	Asn	His	His	Phe	Met	Cys	Glu	Ala	Glu	Gly	Glu	Gl
			٠		20					25					30		
		Lys	Pro	Tyr	Glu	Gly	Thr	Gln	Met-	Glu	Asn	Ile	Lys	Val	Thr	Lys	Gly
10				35	-				40			,	•	45			
		Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Phe
15	٠ ـــ ٠		50			,		55					60				
		Gly	Ser	Val	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe
20	-	65					70				•	75					80
		Lys	Gln	Ser	Phe	Pro	Gľu	Glý	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Тут
						85				,	90					95	
25		Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly
				•	100		,	•		105					110		
30		Asn	Cys		. Val	Туг	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro
				115					120					125			
35		Asn		Pro	Val	Met	Gln		Lys	Thr	Gln	Gly		Glu	Pro	Cys	Cys
		01	130					135				_	140		<u>.</u>		
4			Met	Arg	Tyr	Ihr		Asp	Gly	Val	Leu		Gly	Gln	Thr	Leu	
40		145	Lau	1	Cua	A 3 =	150			112 -		155 Th	C				160
		Ala	rea	Lys	Cys		ASP	GIA	ASI	HIS		ınr	Cys	HIS	Leu		lhr
45		Thr	Tur	Ara	Sar	165	Lvc	41a	410	Lva	170	1	C1=		D	175	DL -
. •	• .	1111	1 7 1	urg	Ser 180	LYS	Lys	VIG	піа	185	via	Leu	GIII	met	190	rro	rne
		His	Phe	Ser	Asp	Hic	Δτσ	Pro	Glu		Va1	Lvc	Val	Sor		A on	C1
50				195					200	110	141	Lys		205	GIU	usii	оту
		Thr	Len		Glu	Gln	Hie	GIn		Ser	۱ <sub>د</sub> ۷	Ala	Δ20		Cvc	GI n	Th-
55			210			<b>4411</b>		215	J-01	561		vía	220	1 7 1	Uys	9111	1111
					•			2.0					220				

Cys Pro Ser Lys Leu Gly His Asn

225 230 (210) 18 <211> 699 <212> DNA <213> Cnidopus japonicus <400> 18 atg gct tcc aaa atc agc gac aat gta cgt atc aag tta tat atg gag 48 Met Ala Ser Lys Ile Ser Asp Asn Val Arg Ile Lys Leu Tyr Met Glu ggc aca gtc aac aat cat cac ttc atg tgc gaa gct gaa gga gag ggc 96 Gly Thr Val Asn Asn His His Phe Met Cys Glu Ala Glu Gly Glu Gly 20 25 30 aag cca tac gag gga act caa atg gag aac ata aaa gtc acc aaa gga 144 Lys Pro Tyr Glu Gly Thr Gln Met Glu Asn Ile Lys Val Thr Lys Gly 35 ggc cct ctg ccg ttc tct ttt gat atc ttg acg cct aac tgc caa ttt 192 Cly Pro Leu Pro Phe Ser Phe Asp Ile Leu Thr Pro Asn Cys Gln Phe gga agc gta gcc ata acc aag tat aca tca ggg att cca gac tac ttt 240 Gly Ser Val Ala Ile Thr Lys Tyr Thr Ser Gly Ile Pro Asp Tyr Phe 65 75 aag caa tot tit oot gaa gga tit acc tgg gaa aga acc aca atc tac 288 Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr 85 gaa gat ggg gct tac ctt aca act caa caa gaa acc aaa ctt gat gga 336

	Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	GLy	
5				100	•				105					110			
	aat	tgc	ctc	gtc	tac	aat	att	aaa	atc	ctt	gga	tgt	aat	ttt	ссс	ccc	384
10	Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro	
			115	•				120		V			125			÷	
	aat	ggt	cct	gtg	atg	cag	aag	aaa	acc	caa	ggc	tgg	gaa	ccc	tgt	tgc	432
	Asn	Gly	Pro	Val	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys	
		130					135		•		٠	140					
20	gag	atg	cgc	tat	aca	cgt	gat	ggt	gtg	cta	tgt.	ggc	caa	aca	tta	atg	480
	Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met	
25	145					150		·. ,		<i>:</i>	155					160	
		**		tgc								,					528
	Ala	Leu	Lys	Cys	Ala	Asp	Gly	Asn	His	Leu	Thr	Cys	His	Leu	Arg	Thr	
30	•	•			165					170					175		,
	act	tac	agg	tcc	aaa	aag	gca	gca	aag	gcg	ttg	cag	atg	cca	ccc	ttc	576
35	Thr	Tyr	Arg	Ser	Lys	Lys	Ala	Ala	Lys	Ala	Leu	Gln	Met	Pro	Pro	Phe	
• • •		٠		180			•		185					190	٠		•
40				gac									• .				624
	His	Phe	Ser	Asp	His	Arg	Pro			Val	Lys	Val	Ser	Glu	Asn	Gly	
			195	٠				200					205				
45	aca	cta	ttt	gaa	cag	cac	gaa	agt	tca	gtg	gcc	agg	tac	tgt	caa	aca	672
	Thr	Leu	Phe	Glu	Gln	His	Glu	Ser	Ser	Val	Ala	Arg	Tyr	Cys	Gln	Thr	
50		210				,	215	٠				220			-		•
	tgc	cca	tct	aaa	ctt	ggt	cac	aat	taa		-	٠,					699
	Cys	Pro	Ser	Lys	Leu	Gly	His	Asn			•						
55	225	*				230											

	<210	0> 19	9 .			٠										
	<21	1> 2:	32						٠.							
	<213	2> PI	RT												٠	
	<21	3> Cr	nidoj	ous :	japor	nicus	5									
		0> 19				,										
				Lvs	Ile	Ser	Asp	Asn	Val	Arg	Tle	i.vs	Leu	Tvr	Met	Glu
	1			_,_	5					10		, .		-,-	15	010
	Giv	Thr	Val	Asn		His	His	Phe	Met		Glu	Ala	Glu	Glv		Glv
•	01)	1111	, 41	20		*****			25	0,5	OIU,	nia		: 30	oru	01)
	lve	Pro	Tur			Thr	Gln	Met		A:sn	: م ۲۱	Īve			lve	Clv
	Lys	110	35	010	ULY	1111	GIII	40	oru	nou.	110	LJS	45	1111	Lys	Gly
	Clv.	D-c		Dro	Dho	Sor	Dho		Tla	Lou	Thr	Dro		Cva	Cln	U; a
	ОТУ		rea	110	1 116	261		Asp	116	Leu	1111		YSII	Cys	· GIII	. 1112
$(x,y) = (x,y) + \frac{x}{2} = \frac{x}{2}$	01	50	υ-1	41.	71.	T\	55	.· T	TL	· ·	C1	60	<b>D</b>	:	т	DL -
•		2er	Aal	Ala	116		Lys	Tyr	ınr	Ser		116	rro	Asp	lyr	
ı	65			~.	_	70					75					80
· · · · · · · · · · · · · · · · · · ·	Lys	Gin	Ser	Phe		Glu	Gly	Phe	ihr		Glu	Arg	ihr	Thr		lyr
. •					85 					90			<u>.</u> .		95	
	Glu	Asp	Gly		Tyr	Leu	Thr	Thr		GIn	Glu	Thr			Asp	Gly
			_	100					105					110		
	Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	lle	Leu	Gly	Cys		Phe	Pro	Pro
5			115					120				٠	125			
	Asn	Gly	Pro	Val	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys
		130					135			. , .		140		٠		
)	Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met
	145					150					155					160
	Ala	Leu	Lys	Cys	Ala	Asp	Gly	Asn	His	Leu	Thr	Cys	His	Leu	Arg	Thr
					165					170			•		175	

Thr Tyr Arg Ser Lys Lys Ala Ala Lys Ala Leu Gln Met Pro Pro Phe 180 185 190 His Phe Ser Asp His Arg Pro Glu Ile Val Lys Val Ser Glu Asn Gly 195 200 205 10 Thr Leu Phe Glu Gln His Glu Ser Ser Val Ala Arg Tyr Cys Gln Thr 215 210 220 Cys Pro Ser Lys Leu Gly His Asn 15 230 225 <210> 20 <211> 699 <212> DNA <213> Cnidopus japonicus <400> 20 atg gct tcc aaa atc agc gac aat gta cgt atc aag tta tat atg gag 48 Met Ala Ser Lys Ile Ser Asp Asn Val Arg Ile Lys Leu Tyr Met Glu 10 15 ggc aca gtc aac aat cat cac ttc atg tgc gaa gct gaa gga gag ggc Gly Thr Val Asn Asn His His Phe Met Cys Glu Ala Glu Gly Glu Gly 20 25 aag cca tac gag gga act caa atg gag aac ata aaa gtc acc aaa gga 144 Lys Pro Tyr Glu Gly Thr Gln Met Glu Asn Ile Lys Val Thr Lys Gly 35 ggc cct ctg ccg ttc tct ttt gat atc ttg acg cct aac tgc caa cat 192 Gly Pro Leu Pro Phe Ser Phe Asp Ile Leu Thr Pro Asn Cys Gln His 50 60 gga agc gta gcc ata acc aag tat aca tca ggg att cca gac tac ttt 240

		Gly	Ser	Val	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe	
5		65					70			٠.		75					80	
•		aag	caa	tct	ttt	cct	gaa	gga	ttt	acc	tgg	gaa	aga	acc	aca	atc	tac	288
	• .	Lys	Gln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr	
10	-			٠.		85	٠	:			90			•		95		
•		gaa	gat	ggg	gct	tac	ctt	aca	act	caa	caa	gaa	acc	aaa	ctt	gat	gga	336
15		Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly	
	-				100			•		105	·	· · .			110	·		-
	•	aat	tgc	ctc	gtc	tac	aat	att	aaa	atc	ctt	gga	tgt	aat	ttt	ccc	ccc	384
20	•	Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro	
	٠.			115					120		٠,	٠		125				
25		aat	ggt	cct	gtg	atg	cag	aag	aaa	acc	caa	ggc	tgg	gaa	ccc	ţgt	tgc	432
		Asn	Gly	Pro	Val	Met	Ğln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Cys	Cys	٠
		•	130					135		٠			140					
30		gag	atg	cgc	tat	aca	cgt	gat	ggt	gtg	çta	tgt	ggc	caa	aca	tta	atg	480
		Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met	
35		145					150		·			155					160	
		gca	ctt	aaa	tgc	gcc	gat	ggg	aac	cac	ctc	act	tgc	cat	ctg	aga	act	528
		Ala	Leu	Lys	Cys	Ala	Asp	Gly	Asn	His	Leu	Thr	Cys	His	Leu	Arg	Thr	
<b>40</b>					. ]	165		,			170	· · ·	•			175		
		act	tac	agg	tcc	aaa	aag	gca	gca	aag	gcg	ttg	cag	atg	cca	ccc	ttc	576
45		Thr	Tyr	Arg	Ser	Lys	Lys	Ala	Ala	Lys	Ala	Leu	Gln	Met	Pro	Pro	Phe	
				• •	180					185					190			
50		cat	ttt	tca	gac	cat	cgt	cct	gaa	ata	gtg	aag	gtt	tca	gag	aac	ggc	624
30	•				Asp					,				·				
				195	-		_		200				-	205			•	
55		aca	cta		gaa	cag	cac	gaa	agt	tca	gtg	gcc	agg		tet.	caa	aca	672
		_		-			-	_				<u> </u>			-0•			- · ••

tgc cca tct aaa ctt ggt cac aat taa 695  Cys Pro Ser Lys Leu Gly His Asn  225 230  (210> 21  (211> 232  (212> PRT  (213> Cnidopus japonicus (400> 21  Met Ala Ser Lys Ile Ser Asp Asn Val Arg Ile Lys Leu Tyr Met Glu  1 5 10 15  Gly Thr Val Asn Asn His His Phe Met Val Glu Ala Glu Gly Glu Gly  20 25 30  Lys Pro Tyr Glu Gly Thr Gln Met Glu Asn Ile Lys Val Thr Lys Gly  35 40 45  Gly Pro Leu Pro Phe Ser Phe Asp Ile Leu Thr Pro Asn Cys Gln Met  50 55 60  Gly Ser Val Ala Ile Thr Lys Tyr Thr Ser Gly Ile Pro Asp Tyr Phe  65 70 75 80  Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr  85 90 95  Glu Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly  100 105 110  Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro		Thr	Leu	Phe	Glu	Gln	His	Glu	Sér	Ser	Val	Ala	Arg	Tyr	Cys	Gln	Thr	
Cys Pro Ser Lys Leu Gly His Asn 225 230  15	5		210					215		٠.			220					
225 230  230  2210 21  2211 232  2212 PRT  20  213 Cnidopus japonicus  2400 21  25 Met Ala Ser Lys Ile Ser Asp Asn Val Arg Ile Lys Leu Tyr Met Glu  1 5 10 15  Gly Thr Val Asn Asn His His Phe Met Val Glu Ala Glu Gly Glu Gly  20 25 30  Lys Pro Tyr Glu Gly Thr Gln Met Glu Asn Ile Lys Val Thr Lys Gly  35 40 45  Gly Pro Leu Pro Phe Ser Phe Asp Ile Leu Thr Pro Asn Cys Gln Met  50 55 60  Gly Ser Val Ala Ile Thr Lys Tyr Thr Ser Gly Ile Pro Asp Tyr Phe  65 70 75 80  Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr  85 90 95  Glu Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly  100 105 110  Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro	•	tgc	cca	tct	aaa	ctt	ggt	cac	aat	taa								699
225 230  (210) 21 (211) 232 (212) PRT (213) Cnidopus japonicus (400) 21  25 Met Ala Ser Lys Ile Ser Asp Asn Val Arg Ile Lys Leu Tyr Met Glu 1 5 10 15 Gly Thr Val Asn Asn His His Phe Met Val Glu Ala Glu Gly Glu Gly 20 25 30  Lys Pro Tyr Glu Gly Thr Gln Met Glu Asn Ile Lys Val Thr Lys Gly 35 40 45 Gly Pro Leu Pro Phe Ser Phe Asp Ile Leu Thr Pro Asn Cys Gln Met 50 55 60 Gly Ser Val Ala Ile Thr Lys Tyr Thr Ser Gly Ile Pro Asp Tyr Phe 65 70 75 80  45 Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr 85 90 95 Glu Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly 100 105 110  Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro		Cys	Pro	Ser	Lys	Leu	Gly	His	Asn					_				•
<211> 232         <212> PRT         <213> Cnidopus japonicus         <400> 21         25       Met Ala Ser Lys Ile Ser Asp Asn Val Arg Ile Lys Leu Tyr Met Glu         1       5       10       15         30       Gly Thr Val Asn Asn His His Phe Met Val Glu Ala Glu Gly Glu Gly       20       25       30         Lys Pro Tyr Glu Gly Thr Gln Met Glu Asn Ile Lys Val Thr Lys Gly       35       40       45         Gly Pro Leu Pro Phe Ser Phe Asp Ile Leu Thr Pro Asn Cys Gln Met       50       55       60         Gly Ser Val Ala Ile Thr Lys Tyr Thr Ser Gly Ile Pro Asp Tyr Phe       65       70       75       80         45       Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr       85       90       95         50       Glu Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly       100       105       110         Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro       75       80	10	225					230											
<211> 232         <212> PRT         <213> Cnidopus japonicus         <400> 21         25       Met Ala Ser Lys Ile Ser Asp Asn Val Arg Ile Lys Leu Tyr Met Glu         1       5       10       15         30       Gly Thr Val Asn Asn His His Phe Met Val Glu Ala Glu Gly Glu Gly       20       25       30         Lys Pro Tyr Glu Gly Thr Gln Met Glu Asn Ile Lys Val Thr Lys Gly       35       40       45         Gly Pro Leu Pro Phe Ser Phe Asp Ile Leu Thr Pro Asn Cys Gln Met       50       55       60         Gly Ser Val Ala Ile Thr Lys Tyr Thr Ser Gly Ile Pro Asp Tyr Phe       65       70       75       80         45       Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr       85       90       95         50       Glu Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly       100       105       110         Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro       75       80																	÷	
20	15	<210	> 21	l				,	. •					. •				
20		<211	> 23	32		. <del></del> .												
<213> Cnidopus japonicus         <400> 21         25       Met Ala Ser Lys Ile Ser Asp Asn Val Arg Ile Lys Leu Tyr Met Glu         1       5       10       15         30       Gly Thr Val Asn Asn His His Phe Met Val Glu Ala Glu Gly Glu Gly       20       25       30         Lys Pro Tyr Glu Gly Thr Gln Met Glu Asn Ile Lys Val Thr Lys Gly       35       40       45         Gly Pro Leu Pro Phe Ser Phe Asp Ile Leu Thr Pro Asn Cys Gln Met       50       55       60         Gly Ser Val Ala Ile Thr Lys Tyr Thr Ser Gly Ile Pro Asp Tyr Phe       65       70       75       80         45       Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr       85       90       95         60       Glu Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly       100       105       110         Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro       75       80	20	<212	> Pi	RT										•				
25 Met Ala Ser Lys Ile Ser Asp Asn Val Arg Ile Lys Leu Tyr Met Glu  1 5 10 15  Gly Thr Val Asn Asn His His Phe Met Val Glu Ala Glu Gly Glu Gly  20 25 30  Lys Pro Tyr Glu Gly Thr Gln Met Glu Asn Ile Lys Val Thr Lys Gly  35 35 40 45  Gly Pro Leu Pro Phe Ser Phe Asp Ile Leu Thr Pro Asn Cys Gln Met  40 50 55 60  Gly Ser Val Ala Ile Thr Lys Tyr Thr Ser Gly Ile Pro Asp Tyr Phe  65 70 75 80  45 Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr  85 90 95  Glu Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly  100 105 110  Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro	20	₹213	> Cr	ni dop	ous .	japoi	nicus	S										
1 5 10 15  Gly Thr Val Asn Asn His His Phe Met Val Glu Ala Glu Gly Glu Gly 20 25 30  Lys Pro Tyr Glu Gly Thr Gln Met Glu Asn Ile Lys Val Thr Lys Gly 35 35 40 45  Gly Pro Leu Pro Phe Ser Phe Asp Ile Leu Thr Pro Asn Cys Gln Met 40 50 55 60  Gly Ser Val Ala Ile Thr Lys Tyr Thr Ser Gly Ile Pro Asp Tyr Phe 65 70 75 80  45 Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr 85 90 95  Glu Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly 100 105 110  Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro	•	<400	> 21									••						
Gly Thr Val Asn Asn His His Phe Met Val Glu Ala Glu Gly Glu Gly  20 25 30  Lys Pro Tyr Glu Gly Thr Gln Met Glu Asn Ile Lys Val Thr Lys Gly  35 35 40 45  Gly Pro Leu Pro Phe Ser Phe Asp Ile Leu Thr Pro Asn Cys Gln Met  50 55 60  Gly Ser Val Ala Ile Thr Lys Tyr Thr Ser Gly Ile Pro Asp Tyr Phe  65 70 75 80  45  Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr  85 90 95  Glu Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly  100 105 110  Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro	25	Met	Ala	Ser	Lys	Ile	Ser	Asp	Asn	Val	Arg	Ile	Lys	Leu	Tyr	Met	Glu	
20 25 30  Lys Pro Tyr Glu Gly Thr Gln Met Glu Asn Ile Lys Val Thr Lys Gly  35 35 40 45  Gly Pro Leu Pro Phe Ser Phe Asp Ile Leu Thr Pro Asn Cys Gln Met  50 55 60  Gly Ser Val Ala Ile Thr Lys Tyr Thr Ser Gly Ile Pro Asp Tyr Phe  65 70 75 80  Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr  85 90 95  Glu Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly  100 105 110  Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro		1	٠.			5					10					15		•
Lys Pro Tyr Glu Gly Thr Gln Met Glu Asn Ile Lys Val Thr Lys Gly  35	<i>30</i>	Gly	Thr	Val	Asn	Asn	His	His	Phe	Met	Val	Glu	Ala	Glu	Gly	Glu	Gly	
35					20					25				•	30	•		
Gly Pro Leu Pro Phe Ser Phe Asp Ile Leu Thr Pro Asn Cys Gln Met  50 55 60  Gly Ser Val Ala Ile Thr Lys Tyr Thr Ser Gly Ile Pro Asp Tyr Phe  65 70 75 80  Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr  85 90 95  Glu Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly  100 105 110  Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro		Lys	Pro	Tyr	Glu	Gly	Thr	Gln	Met	Glu	Asn	Ile	Lys	Val	Thr	Lys	Gly	
50 55 60  Gly Ser Val Ala Ile Thr Lys Tyr Thr Ser Gly Ile Pro Asp Tyr Phe 65 70 75 80  Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr 85 90 95  Glu Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly 100 105 110  Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro	35			35					40			•		45			٠.	
Gly Ser Val Ala Ile Thr Lys Tyr Thr Ser Gly Ile Pro Asp Tyr Phe 65 70 75 80  Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr 85 90 95  Glu Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly 100 105 110  Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro	. •	Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Met	
Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr  85  90  95  61u Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly  100  105  110  Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro	40		50					55					60		. •			
Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr  85  90  95  Glu Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly  100  105  110  Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro		Gly	Ser	Yal	Ala	Ile	Thr	Lys	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe	
So Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Thr Thr Ile Tyr  85 90 95  Glu Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly  100 105 110  Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro		65					70					75					80	
Glu Asp Gly Ala Tyr Leu Thr Thr Gln Gln Glu Thr Lys Leu Asp Gly 100 105 110 Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro	45	Lys	G1n	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr	
100 105 110  Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro	•					85	-				90			٠		95	•	٠
Asn Cys Leu Val Tyr Asn Ile Lys Ile Leu Gly Cys Asn Phe Pro Pro	50	Glu .	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly	
55	;				100					105					110		٠.	
	55	Asn	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro	
				115	• .				120					125				

	Asn	Gly	Pro	Val	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Ser	Cys	
i .		130					135					140					
	Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met	
	145					150					155					160	
9	Ala	Leu	Lys	Cys	Ala	Asp	Gly	Asn	His	Leu	Thr	Cys	His	Leu	Arg	Thr	
					165					170					175		
5 .	Thr	Tyr	Arg	Ser	Lys	Lys	Ala	Ala	Lys	Ala	Leu	Gl'n	Met	Pro	Pro	Phe	
-				180					185					190	•		
	His	Phe	Ser	Asp	His	Arg	Leu	Glu	lle	Val	Lys	Val	Ser	Glu	Asn	Gly	
0			195	-			•	200	•				205			•	
	Thr	Leu	Phe	Glu	Gln	His	Glu	Ser	Ser	Val	Ala	Arg	Tyr	Cys	Gln	Thr	
5		210					215			٠.	,	220					
	Cys	Pro	Ser	Lys	Leu	Gly	His	Asn.			٠		•				
	225					230											
<i>.</i>						•				•							
	<210	)> 22	2														
5	<21	L> 69	99								•					•	· ;
*.	<212	2> D1	AA											:			
0	<213	3> Cr	nidop	ous .	japor	nicus	5								,		. ,
	<400	)> 22	2 .														
	atg	gct	tcc	aaa	atc	agc	gac	aat	gta	cgt	atc	aag	tta	tat	atg	gag	48
5	Met	Ala	Ser	Lys	Ile	Ser	Asp	Asn	Val	Arg	Ile	Lys	Leu	Tyr	Met	Glu	
	1				5					10			•		15		
<b>o</b>	ggc	aca	gtc	aac	aat	cat	cac	ttc	atg	gtc	gaa	gct	gaa	gga	gag	ggc	96
	Gly	Thr	Val	Asn	Asn	His	His	Phe	Met	Val	Glu	Ala	Glu	Gly	Glu	Gly	
				20					25					30	٠		
5	aag	cca	tac	gag	gga	act	caa	atg	gag	aac	ata	aaa	gtc	acc	aaa	gga	144
								,									

•	Lys	Pro	Tyr	Glu	Gly	Thr	Gln	Met	Glu	Asn	Ile	Lys	Val	Thr	Lys	Gly	
5			35	,				40	٠.		.•		45				
	ggc	cct	ctg	ccg	ttc	tct	ttt	gat	atc	ttg	acg	cct	aac	tgc	caa	tat	192
	Gly	Pro	Leu	Pro	Phe	Ser	Phe	Asp	Ile	Leu	Thr	Pro	Asn	Cys	Gln	Met	
10		50	•				55		,			60		:	٠		
	gga	agc	gta	gcc	ata	acc	aag	tat	aca	tca	ggg	att	cca	gac	tac	ttt	240
15	Gly	Ser	Val	Ala	Ile	Thr	Lýs	Tyr	Thr	Ser	Gly	Ile	Pro	Asp	Tyr	Phe	
	65			٠.		70					75	•	•			80	
· .	aag	caa	tct	ttt	cct	gaa	egg	ttt	эсс	tgg	gaa	aga	acc	aca	atc	tac	288
20	Lys	Gln	Ser	Phe	Pro	Glu	Gly	Phe	Thr	Trp	Glu	Arg	Thr	Thr	Ile	Tyr	ē.
					85	1 T	•			90					95		
25	gaa	gat	ggg	gct	tac	ctt	aca	act	caa	caa	gaa	асс	aaa	ctt	gat	gga	336
	Glu	Asp	Gly	Ala	Tyr	Leu	Thr	Thr	Gln	Gln	Glu	Thr	Lys	Leu	Asp	Gly	
30		, · · ·		100					105			•		110	1	. •	
	aat	tgc	ctc	gtc	tac	aat	att	aaa	atc	ctt	gga	tgt	aat	ttt	ccc	ccc	384
	Asn.	Cys	Leu	Val	Tyr	Asn	Ile	Lys	Ile	Leu	Gly	Cys	Asn	Phe	Pro	Pro	
35			115	٠.				120			• .		125				
	aat	ggt	cct	gtg	atg	cag	aag	aaa	acc	caa	ggc	tgg	gaa	ccc	agt	tgc	432
40	Asn	Gly	Pro	Val	Met	Gln	Lys	Lys	Thr	Gln	Gly	Trp	Glu	Pro	Ser	Cys	
	,	130					135	,		. ·		140					,
	gag	atg	cgc	tat	aca	cgt	gat	ggt	gtg	cta	tgt	ggc	caa	aca	tta	atg	480
45	Glu	Met	Arg	Tyr	Thr	Arg	Asp	Gly	Val	Leu	Cys	Gly	Gln	Thr	Leu	Met	
	145	· :			-	150				•	155					160	÷
50	gca	ctt	aaa	tgc	gcc	gat	ggg	aac	cac	ctc	act	tgc	cat	ctg	aga	act	528
	Ala	Leu	Lys	Cys	Ala	Asp	Gly	Asn	His	Leu	Thr	Cys	His	Leu	Arg	Thr	
				• •	165					170					175		
. <b>55</b>	act	tac	agg	tcc	aaa	aag	gca	gca	aag	gcg	ttg	cag	atg	cca	ccc	ttc	576
•				•			•					•					

Thr Tyr Arg Ser Lys Lys Ala Ala Lys Ala Leu Gln Met Pro Pro Phe 180 185 190 cat ttt tca gac cat cgt ctt gaa ata gtg aag gtt tca gag aac ggc 624 His Phe Ser Asp His Arg Leu Glu Ile Val Lys Val Ser Glu Asn Gly 195 200 205 aca cta ttt gaa cag cac gaa agt tca gtg gcc agg tac tgt caa aca 672 Thr Leu Phe Glu Gln His Glu Ser Ser Val Ala Arg Tyr Cys Gln Thr 210 215 220 699 tgc cca tct aaa ctt ggt cac aat taa Cys Pro Ser Lys Leu Gly His Asn

Claims

225

- 1. A chromoprotein derived from Cnidopus japonicus having the following properties:
  - (1) the absorption maximum wavelength is 610 nm, and fluorescence is not emitted:
  - (2) the molar absorption coefficient is 66,700 at 610 nm; and
  - (3) the pH sensitivity of light-absorbing property is stable at between pH 4 and pH 10.
- 2. A chromoprotein having either one of the following amino acid sequences:
  - (a) the amino acid sequence shown in SEQ ID NO: 1; and
  - (b) an amino acid sequence comprising a deletion, substitution and/or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1, and having light-absorbing properties.
- 3. A chromoprotein capable of emitting fluorescence, which has an amino acid sequence, wherein, with respect to the amino acid sequence shown in SEQ ID NO: 1, alanine as an amino acid residue at position 28 is substituted by glycine, glutamic acid as an amino acid residue at position 41 is substituted by methionine, cysteine as an amino acid residue at position 145 is substituted by serine, and threonine as an amino acid residue at position 158 is substituted by isoleucine.
- 4. A chromoprotein having an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by leucine with respect to the amino acid sequence shown in SEQ ID NO: 1.
- A chromoprotein having an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by methionine with respect to the amino acid sequence shown in SEQ ID NO: 1.
- 6. A chromoprotein having an amino acid sequence, wherein glutamic acid as an amino acid residue at position 41 is substituted by leucine, and phenylalanine as an amino acid residue at position 80 is substituted by glycine, with respect to the amino acid sequence shown in SEQ ID NO: 1.
  - 7. A chromoprotein capable of emitting fluorescence, which has an amino acid sequence wherein tyrosine as an

amino acid residue at position 64 is substituted by phenylalanine with respect to the amino acid sequence shown in SEQ ID NO: 1.

- A chromoprotein capable of emitting fluorescence, which has an amino acid sequence wherein tyrosine as an amino acid residue at position 64 is substituted by histidine with respect to the amino acid sequence shown in SEQ ID NO: 1.
  - 9. A chromoprotein capable of emitting fluorescence, which has an amino acid sequence, wherein cysteine as an amino acid residue at position 26 is substituted by valine, cysteine as an amino acid residue at position 143 is substituted by serine, and proline as an amino acid residue at position 199 is substituted by leucine, with respect to the amino acid sequence shown in SEQ ID NO: 1.
  - 10. A DNA encoding the protein of any of claims 1 to 9.
- 5 11. A DNA of either one of followings:


10

- (a) DNA encoding the amino acid sequence shown in SEQ ID NO: 1; and
- (b) DNA encoding an amino acid sequence, which comprises a deletion, substitution and/or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1, and has light-absorbing properties.
- 12. A DNA having either one of the following nucleotide sequences:
  - (a) the nucleotide sequence shown in SEQ ID NO: 2; and
  - (b) a nucleotide sequence comprising a deletion, substitution and/or addition of one or several nucleotides with respect to the nucleotide sequence shown in SEQ ID NO: 2, and encoding a protein having light-absorbing properties.
- 13. A DNA having the nucleotide sequence shown in any one of SEQ ID NOS: 12, 14, 16, 18, 20, or 22.
- 14. A recombinant vector having the DNA of any of claims 10 to 13.
- 15. A transformant having the DNA of any of claims 10 to 13 or the recombinant vector of claim 14.
- 16. A fusion protein composed of the chromoprotein of any of claims 1 to 9 and another protein.
  - 17. A method for analyzing a physiologically active substance, which is characterized in that the FRET (fluorescence resonance energy transfer) method is applied using the chromoprotein of any of claims 1 to 9 as an acceptor protein.
- 18. A light-absorbing reagent kit comprising the chromoprotein of any of claims 1 to 9, the DNA of any of claims 10 to 13, the recombinant vector of claim 14, the transformant of claim 15, or the fusion protein of claim 16.

40

Fig. 1

KGr 20uM



\*Abs

Fig. 2






Fig. 3 KGr A28G,E41M,C145S,T158I



Flg. 4



Y64L

Fig. 5






Fig. 6

### E41L,F80G

abs




Fig. 7






Fig. 8

# Y64F

abs




Fig. 9




Fig. 10




Fig. 11





Fig. 12



### INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP03/07336

4 01 10	and a most on arm month (1 mm)		<del></del>						
A. CLASS	SIFICATION OF SUBJECT MATTER C1 <sup>7</sup> C12N15/12, 1/21, 5/10, C0 <sup>-</sup>	7214/425 10/00 COIN21	/70						
1110.	CI CI2NIS/12, 1/21, 5/10, CO	7K147455, 19700, GUINZI	, ,						
		•							
According t	to International Patent Classification (IPC) or to both n	ational classification and IPC							
B. FIELD	S SEARCHED	· · · · · · · · · · · · · · · · · · ·	······································						
	ocumentation searched (classification system followed	by classification symbols)	<del></del>						
	C17 C12N15/00-15/90, 1/21, 5/		9/00,						
	G01N21/78	•							
	•								
Documentat	tion searched other than minimum documentation to th	e extent that such documents are included	in the fields searched						
			ar are trong sements						
			•						
Electronic d	lata base consulted during the international search (nam	ne of data base and where practicable sea	mb terms used)						
MEDL	INE (STN), WPI/BIOSIS (DIALOG),	JSTPlus (JOIS)	ion arms ascay						
GenB	ank/EMBL/DDBJ/GeneSeq, SwissPr	ot/PIR/GeneSeq							
C DOCII	MENTS CONSIDERED TO BE RELEVANT								
- DOOD	<u> </u>								
Category*	Citation of document, with indication, where ap		Relevant to claim No.						
Χ.	Atsushi MIYAWAKI, "Shiho Dob		1-18						
	shitsu", Midoriishi, March,	2002, No.13, pages	·						
,	1 to 4								
A	WO 01/27150 A2 /CLONTECH TAE	ACPATORIES INC \	1-18						
	A WO 01/27150 A2 (CLONTECH LABORATORIES INC.), 1- 19 April, 2001 (19.04.01),								
	& EP 1305412 A2								
·									
, ,		•							
.									
	<u> </u>		<del></del>						
Furthe	er documents are listed in the continuation of Box C.	See patent family annex.							
	categories of cited documents:	"T" later document published after the inte							
	ent defining the general state of the art which is not ared to be of particular relevance	priority date and not in conflict with to understand the principle or theory und							
"E" earlier	document but published on or after the international filing	"X" document of particular relevance; the	claimed invention cannot be						
"L" docume	ent which may throw doubts on priority claim(s) or which is	considered novel or cannot be considered novel or cannot be considered above step when the document is taken alone							
cited to	establish the publication date of another citation or other	"Y" document of particular relevance; the	claimed invention cannot be						
"O" docum	reason (as specified) ent referring to an oral disclosure, use, exhibition or other	considered to involve an inventive ste combined with one or more other such							
means "P" docume	ent published prior to the international filing date but later	combination being obvious to a person  "&" document member of the same patent							
	e priority date claimed	a document memoer of the same patent	tainty						
	actual completion of the international search	Date of mailing of the international sear							
27 J	une, 2003 (27.06.03)	15 July, 2003 (15.0	07.03)						
			.*						
	nailing address of the ISA/	Authorized officer	• • • • • • • • • • • • • • • • • • • •						
Japa	nese Patent Office								
Faccimile M	n :	Telephone No.							
Facsimile N	v. ·	1 VIOPIDITE ETO.	•						

Form PCT/ISA/210 (second sheet) (July 1998)